{"id":"xr-ntx-380-mg-intramuscular-injection","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Injection site reactions (pain, erythema, induration)"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Insomnia"},{"rate":"5-10","effect":"Anxiety"},{"rate":"5","effect":"Hepatotoxicity (elevated liver enzymes)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naltrexone is a competitive opioid receptor antagonist that binds to mu, delta, and kappa opioid receptors with high affinity. The extended-release intramuscular formulation provides sustained drug delivery over approximately one month, maintaining therapeutic opioid receptor blockade and reducing the reinforcing effects of opioid use. This mechanism helps prevent relapse and supports abstinence in patients with opioid use disorder.","oneSentence":"XR-NTX 380 mg is an extended-release formulation of naltrexone that blocks opioid receptors to prevent opioid use and reduce cravings in opioid use disorder.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:44.689Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder (prevention of relapse and maintenance of abstinence)"}]},"trialDetails":[{"nctId":"NCT05028062","phase":"PHASE4","title":"Naltrexone in AUD Reward Drinkers","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-03-07","conditions":"Alcohol Use Disorder, Alcoholism","enrollment":60},{"nctId":"NCT04219540","phase":"PHASE4","title":"Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-01-07","conditions":"Opioid-use Disorder","enrollment":675},{"nctId":"NCT02478489","phase":"PHASE4","title":"Alcohol Disorder hOsPital Treatment Trial","status":"COMPLETED","sponsor":"Boston University","startDate":"2016-06","conditions":"Heavy Drinking, Alcohol Dependence, Alcohol Use Disorder","enrollment":248},{"nctId":"NCT01717963","phase":"PHASE3","title":"Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway","status":"COMPLETED","sponsor":"University of Oslo","startDate":"2012-10","conditions":"Opioid Dependence","enrollment":166},{"nctId":"NCT01449565","phase":"PHASE2","title":"Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)","status":"COMPLETED","sponsor":"San Francisco Department of Public Health","startDate":"2012-09","conditions":"Amphetamine-Related Disorders","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vivitrol naltrexone for extended-release injectable suspension"],"phase":"marketed","status":"active","brandName":"XR-NTX 380 mg, intramuscular injection","genericName":"XR-NTX 380 mg, intramuscular injection","companyName":"University of Pennsylvania","companyId":"university-of-pennsylvania","modality":"Small molecule","firstApprovalDate":"","aiSummary":"XR-NTX 380 mg is an extended-release formulation of naltrexone that blocks opioid receptors to prevent opioid use and reduce cravings in opioid use disorder. Used for Opioid use disorder (prevention of relapse and maintenance of abstinence).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}